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Abstract
Background: Elevated levels of biochemical markers of myocardial necrosis have been associated with worsened outcomes
in Acute Respiratory Distress Syndrome (ARDS), but there are few prospective data on this relationship. We investigated
elevated cardiac troponin T (cTnT) levels and their relationship with outcome in patients with ARDS.
Methods: A prospective cohort study of patients with ARDS was conducted at a tertiary-care academic medical center.
Patients had blood taken within 48 hours of ARDS onset and assayed for cTnT. Patients were followed for the outcomes of
60-day mortality, number of organ failures, and days free of mechanical ventilation. Echocardiographic and
electrocardiographic (ECG) data were analyzed for signs of myocardial ischemia, infarction, or other myocardial dysfunction.
Results: 177 patients were enrolled, 70 of whom died (40%). 119 patients had detectable cTnT levels (67%). Median cTnT
level was 0.03 ng/mL, IQR 0–0.10 ng/mL, and levels were higher among non-survivors (P=.008). Increasing cTnT level was
significantly associated with increasing mortality (P=.008). The association between increasing cTnT level and mortality
remained significant after adjustment in a multivariate model (HRadj=1.45, 95% CI 1.17–1.81, P=.001). Elevated cTnT level
was also associated with increased number of organ failures (P=.002), decreased number of days free of mechanical
ventilation (P=.03), echocardiographic wall motion abnormalities (P=0.001), and severity of tricuspid regurgitation (P=.04).
There was no association between ECG findings of myocardial ischemia or infarction and elevated cTnT.
Conclusions: Elevated cTnT levels are common in patients with ARDS, and are associated with worsened clinical outcomes
and certain echocardiographic abnormalities. No association was seen between cTnT levels and ECG evidence of coronary
ischemia.
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Introduction
The Acute Respiratory Distress Syndrome (ARDS) is marked by
considerable cardiovascular strain. This is related to severe
respiratory compromise and hypoxemia caused by endothelial
injury and capillary leak, which result in alveolar filling and
subsequent respiratory failure [1]. Hypoxemia stimulates increased
cardiac output, which can result in myocardial strain in the setting
of decreased oxygen supply and pulmonary hypertension due to
hypoxic pulmonary vasoconstriction, pulmonary endothelial inju-
ry, and in situ thrombosis of the pulmonary vasculature [1]. This
condition is further exacerbated by pulmonary capillary obliter-
ation and lung fibrosis as the syndrome progresses, as well as by
increased intrathoracic pressure from mechanical ventilation [1,2].
Patients with sepsis and septic shock, which are commonly
associated with ARDS, are known to have a syndrome of
myocardial dysfunction at least partly due to inflammation-
induced myocardial apoptosis [3]. Finally, myocardial dysfunction
may be exacerbated by increased myocardial oxygen demand
during critical illness, in the setting of preexisting coronary heart
disease (CHD) restricting coronary arterial blood flow [4]. In sum,
while ARDS is considered a pulmonary disease, the cardiovascular
consequences from this devastating illness are substantial.
Echocardiography is frequently used in the setting of critical
illness to assess cardiovascular structure and function. Patients with
sepsis and septic shock undergo echocardiography to evaluate the
etiology of pulmonary edema and ventricular dysfunction, and the
sensitivity of transthoracic echocardiography for cardiac causes of
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over time in pulmonary artery hemodynamics have been
associated with prognosis in critically ill patients with acute severe
respiratory failure [8]. Likewise, electrocardiography (ECG) is an
important and ubiquitous diagnostic tool in the intensive care unit
(ICU), and has been shown to perform reasonably well in detecting
myocardial ischemia and infarction in ICU patients [9]. Though it
has been demonstrated that elevated levels of cardiac biomarkers
are associated with increased mortality and length of stay in ICU
populations, the underlying cause of such biomarker elevations
remains to be elucidated [10]. No study to date has described the
echocardiographic and ECG characteristics of ICU patients with
elevated cardiac biomarkers and sepsis or ARDS.
Troponin assays are widely used for their diagnostic and
prognostic utility in several clinical settings, including detection or
exclusion of myocardial infarction (MI), heart failure, and
pulmonary embolism, and as supportive tests in sepsis and stroke
[11–13]. We have previously shown that elevated levels of blood
biochemical markers of myocardial necrosis are associated with
increased morbidity and mortality in ARDS patients [14].
However, this analysis was limited by its retrospective nature
and subject to selection bias because the decision to test for
biomarker levels was made by treating clinicians. In addition, the
analysis did not incorporate available echocardiographic and ECG
data, which limited our ability to assess for concomitant acute
coronary syndromes and/or underlying coronary artery disease as
the etiology of abnormal elevations in cardiac biomarkers.
Therefore, we sought to evaluate the association between cardiac
troponin T (cTnT) levels and outcome prospectively in patients
with ARDS, incorporating echocardiographic and ECG data for
the study population. We hypothesized that elevated levels of
cTnT are associated with worse adjusted outcomes in patients with
ARDS above and beyond that informed by more detailed
phenotyping using ultrasound or ECG.
Materials and Methods
Ethics Statement
All aspects of the study protocol were approved by the Partners
Human Research Committee (Protocol #: 1999-P-008607/98).
Informed written consent was obtained from all patients if
possible, or from surrogates.
Study Design and Enrollment
Study patients were drawn from a prospective cohort assembled
for a molecular epidemiology study of ARDS, and were distinct
from those included in our prior study. All adult patients admitted
to the intensive care units (ICU) at our institution (Massachusetts
General Hospital, Boston, MA) from September 1999 to May
2005 were considered for enrollment if they had at least one risk
factor for ARDS from among sepsis, septic shock, pneumonia,
trauma, multiple transfusions, or aspiration. Inclusion and
exclusion criteria were as previously defined [15]. ARDS was
defined as having respiratory failure requiring mechanical
ventilation and meeting North American-European Consensus
Committee (NAECC) criteria for ARDS [16].
Data Collection
Demographic data and data used for calculation of an Acute
Physiology and Chronic Health Evaluation (APACHE) III score
were collected at baseline. Zero was assigned to components of the
APACHE score with missing physiology variables according to the
methods used by the APACHE III investigators. Patients were
screened on each ICU day for presence of ARDS. Data were
recorded until ICU discharge or for 28 days if the patient
remained in the ICU. Patients were followed for the primary
endpoint of 60-day survival. For patients who had been discharged
from the hospital prior to 60-days post-enrollment, phone calls
were made by study staff members to patients’ homes, rehabili-
tation facilities, and skilled nursing facilities to ascertain survival
status. Secondary endpoints were number of ventilator-free days
and average daily multiple organ dysfunction score (MODS),
which was calculated as defined by the criteria of Brussels, with
one point awarded per organ system failure [16].
Data regarding cardiac history and risk factors were obtained
from the history upon admission. Coronary artery disease was
considered to be present if reported by patients or their surrogates,
documented in the medical record, or if there were confirmatory
testing data available. Echocardiographic and ECG data were
retrospectively obtained for patients with available data within 48
hours of blood sample collection for cTnT. Patients underwent
echocardiographic/ECG testing as part of clinical care when
deemed necessary by treating physicians. Left ventricular mass was
calculated using the formula proposed by Devereaux [17]. Mitral
and tricuspid valvular regurgitation were recorded on a 4 point
scale, where 0 represented no regurgitation, 1 was trace, 2 was
mild, 3 was moderate, and 4 was severe regurgitation. ECG results
were obtained from any ECGs available in the patient’s medical
record within 48 hours of blood sample collection for cTnT. As
per the method proposed by Lim et al., each ECG was examined
by a study physician (MR) for the presence or absence of
myocardial ischemia [9]. This was based on the presence or
absence of six findings that may represent acute MI or myocardial
ischemia as per ESC/ACC guidelines: 1) pathologic Q waves, 2)
ST-segment elevation in greater than or equal to two contiguous
leads, 3) ST-segment depression in greater than or equal to two
contiguous leads, 4) symmetric inversion of T waves of $1m mi n
greater than or equal to two contiguous leads, 5) T-wave
flattening, and 6) left bundle branch block (LBBB) [18]. For
quality control purposes, ECG interpretations by the study
physician were compared against formal ECG interpretation
when available. This approach was used for verification purposes
only. If there were important discordances, we had planned to
conduct independent verification by a second study physician, but
no substantive differences were found. The study physician
collecting echocardiogram and ECG data (MR) was blinded to
other study variables and outcomes.
Sample Collection and Testing
Blood samples were taken in EDTA-treated plasma from within
48 hours of fulfillment of all ARDS criteria and stored at a
temperature of –80 C until testing. Levels of cTnT were tested
using Roche Elecsys 2010 immunoassay analyzers according to
manufacturer protocols. Patients were excluded if blood samples
could not be obtained, most commonly due to delays in obtaining
informed consent. When excluded patients were compared to
tested patients, there were no significant differences in terms of
age, gender, ethnicity, APACHE III score, or other relevant
baseline characteristics.
Statistical Analysis
Statistical analyses were performed using SAS software,
version 9.1 (SAS Institute Incorporated, Cary, North Carolina,
USA), as well as with STATA software, version 11.0 (StataCorp,
College Station, Texas, USA). Univariate analyses were per-
formed using Chi-squared tests, two-sample t-tests, or Wilcoxon
rank-sum tests as appropriate. Log transformation was performed
on cTnT levels to achieve normality. To test the effect of
Troponin-T in Acute Respiratory Distress Syndrome
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e40515increasing cTnT log-quartile on mortality rate, patients were
divided into cTnT log-quartiles and the Cochrane-Armitage chi-
square test of trend was applied.
Cox proportional hazards modeling was used to further analyze
the association between increasing cTnT level (modeled as a
continuous variable) and hazard of 60-day mortality. We planned
a priori to adjust this analysis for age and severity of illness (using
APACHE III score modified to remove the age component).
Other covariates of clinical relevance or those with significant
differences in baseline characteristics were considered for inclusion
in this analysis using a backward stepwise selection algorithm with
a P value of #0.2 as the cutoff for inclusion. All demographic,
chronic health, etiologic, and physiologic variables with significant
differences between groups as listed in Table 1 were considered for
inclusion. Two other covariates, history of coronary artery disease
and presence of acute hepatic failure, met criteria for inclusion. In
view of our prior finding that the association of elevated biomarker
levels with mortality is modified by age and severity of illness, we
made the a priori decision to test for effect modification by these
variables by adding interaction terms to the multivariable model.
For further stratified analyses, patients were divided into groups
according to whether cTnT level was above or below a receiver
operator characteristic (ROC)-derived cutpoint. ROC curve
analysis was conducted and the method of Youden was used to
determine the optimal ROC cutpoint for predicting mortality
[19]. This cutpoint (0.036 ng/mL) was similar to the consensus
cutpoint for diagnosis of acute MI [20]. Kaplan-Meier curves were
constructed using cTnT groups as strata and compared using log-
rank testing. Daily MODS scores were compared between patients
in each cTnT strata using repeated-measures ANOVA. Ventila-
tor-free days were compared between strata using Wilcoxon rank-
sum testing.
Echocardiographic and ECG univariate analyses were per-
formed using Chi-squared tests, two-sample t-tests, or Wilcoxon
rank-sum tests as appropriate. P values of #0.05 were considered
statistically significant. For the echocardiographic and ECG
analysis, elevated cardiac marker levels were defined according
to Universal Definition of Myocardial Infarction cut off strategy of
the lowest cut-off providing ,10% imprecision, namely a cTnT
(Roche Diagnostics, Basel, Switzerland) of $0.03 ng/mL.
Results
Study Population and cTnT Levels
177 patients were included in the study. Baseline characteristics
of the study population, shown in Table 1, are sorted by the
primary outcome of 60-day survival. Survivors were significantly
younger than non-survivors and had significantly lower severity of
illness (APACHE III score). Non-survivors were more likely to
have acute hepatic failure or chronic cirrhosis, had significantly
lower mean arterial pressure and urine output, and significantly
higher serum BUN and bilirubin. Overall mortality rate was 40%.
119 patients had detectable cTnT levels (67%). Median cTnT
concentration was 0.03 ng/mL with an interquartile range (IQR)
of 0–0.10 ng/mL.
Among factors contributing to cTnT levels, patients with prior
coronary artery disease (CAD) had significantly higher cTnT levels
than those without CAD, (median 0.08, IQR 0.03–0.30 vs.
median 0.02, IQR 0–0.07, P,0.0001). In addition, patients with
CAD were slightly more likely to have a detectable cTnT level
(86% vs. 61%, P=.002). Because of the nature of the strong
pathophysiologic relationship between CAD and diabetes, we also
evaluated whether patients with reported diabetes had elevated
cTnT levels despite the absence of known CAD. Among the 18
patients who fell into this subgroup, the proportion of detectable
cTnT levels was similar when compared to non-diabetics (67% vs.
60%, P=.58).
Patients with septic shock (n=106) were more likely to have
detectable cTnT, but cTnT was still detected in over half of
patients without septic shock (72% vs. 55%, P=.03). Septic shock
patients had significantly higher cTnT levels (median 0.03, IQR
0–0.12 vs. median 0.02, IQR 0–0.06, P=.03) than those without
septic shock. Among 71 patients without septic shock, only 18 had
no clinical evidence or suspicion of infection; of these patients, 11
had detectable cTnT levels, which was not significantly different
from the proportion of patients with documented or suspected
infection who had detectable cTnT levels (61% vs. 65%, P=.80).
There was no significant difference in cTnT levels between
patients with and without infection (median 0.03, IQR 0–0.1 vs.
median 0.03, IQR 0–.06, P=.46).
cTnT and ARDS Outcome
ARDS nonsurvivors had significantly higher cTnT levels than
survivors (0.042 ng/mL, IQR 0.01–0.21 vs. 0.022, IQR 0–0.08,
P=.008). Mortality increased monotonically with increasing cTnT
log-quartile; this association was statistically significant (Figure 1).
Increasing cTnT level was significantly associated with
increased mortality, with hazard ratio (HR) of 1.33 per 1 ng/
mL increase (95% CI 1.10–1.62, P=0.003). This association
remained significant after adjusting for age, APACHE III score,
presence of acute hepatic failure, and presence of CAD in the
multivariable model (Table 2). Addition of interaction terms to the
model did not show evidence of effect modification by age or
APACHE III score.
Patients were then grouped into strata according to cTnT level
above and below 0.036 ng/mL as described. Kaplan-Meier curves
demonstrating 60-day mortality in each stratum are shown in
Figure 2.
Secondary Outcomes
Patients with cTnT levels above the selected cutpoint had
significantly higher daily MODS scores than those with normal
cTnT levels, as shown in Figure 3 (median 2.5, IQR 1.2–4.1, vs.
median 1.3, IQR 0.7–3.4, P=.002) and had significantly fewer
ventilator-free days (median 0 days, IQR 0–9, vs. median 6 days,
IQR 0–14, P=.03).
Mortality Prediction
By itself, cTnT level had modest ability to predict mortality,
with area under the ROC curve of (AUROC) 0.62 (95% CI 0.53–
0.71), and sensitivity 57%, specificity 66%, negative predictive
value (NPV) 70%, and positive predictive value (PPV) 52% at the
optimal cut-point. By itself, APACHE III curve had an AUROC
of 0.72 (95% CI 0.54–0.80) for predicting mortality, with
sensitivity 64%, specificity 72%, NPV 75%, and PPV 60% at an
APACHE III score of 84. The combined model of cTnT level,
age, APACHE III score, and presence of acute hepatic failure
improved predictive ability, with AUROC 0.81 (95% CI 0.75–
0.87), sensitivity 63%, specificity 82%, NPV 77%, and PPV 70%.
Echocardiographic/ECG Findings and cTnT
Eighty-one patients (46.3%) out of the study population had an
echocardiogram obtained within 48 hours of cardiac biomarker
blood draw. Fifty six patients (32%) had an available ECG within
48 hours of biomarker blood draw. Thirty three patients (19%)
had both an echocardiogram and an ECG available, and sixty
nine patients (39%) had neither. Because ECG and echocardio-
Troponin-T in Acute Respiratory Distress Syndrome
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sought to identify whether patient-specific factors might subject
these data to selection bias. We compared these factors between
the groups of patients who received echocardiogram and ECG
testing and those who did not (table 3). We found that
echocardiograms were obtained more frequently in patients with
pneumonia or septic shock, but that otherwise they were similar
to other patients with regard to age, severity of illness, cTnT
level, diagnosis, and cardiac history. Patients who received ECG
testing were also similar to those who did not, across all of the
measured variables.
Echocardiographic and electrocardiographic characteristics for
the study population are shown in table 4. The median left
ventricular ejection fraction was 57% (intraquartile range 23% to
80%). Nineteen patients (24%) had right ventricular dilation, and
18 (23%) had right ventricular hypokinesis. Sixteen patients (20%)
had echocardiographic regional wall motion abnormalities. In
three of these patients, this was a new finding compared to
Table 1. Baseline Characteristics of Study Population.
Survivors (n=107) Non-survivors (n=70) P
Demographics
Age (years) 56.0 (42.0–71.0) 71.5 (59.0–80.0) ,.0001
Female gender 51 (48%) 28 (40%) .35
Caucasian race 99 (93%) 66 (94%) .64
Acute Illness/ARDS risk factor
Pneumonia 79 (75%) 53 (76%) .86
Septic shock 58 (55%) 46 (66%) .18
Sepsis (w/o shock) 34 (32%) 19 (27%) .49
Trauma 6 (6%) 1 (1%) .16
Aspiration 8 (8%) 8 (11%) .38
Multiple transfusions 8 (8%) 6 (9%) .81
Acute hepatic failure 0 4 (5.7%) .01
Cardiac History
Known coronary artery disease 18 (17%) 26 (37%) .003
Prior myocardial infarction 12 (12%) 14 (20%) .12
Prior coronary artery bypass grafting 4 (4%) 6 (9%) .19
Hyperlipidemia history 20 (19%) 13 (19%) .91
Hypertension history 41 (39%) 33 (47%) .31
Congestive heart failure 8 (8%) 10 (14%) .16
Chronic Health
Cirrhosis 2 (1.9%) 8 (11.4%) .007
Corticosteroid therapy 14 (13%) 16 (23%) .10
Diabetes history 25 (23%) 15 (21%) .74
Smoking history 59 (66%) 40 (65%) .89
Metastatic solid-organ malignancy 3 (2.8%) 2 (2.8%) .99
Baseline physiologic variables
APACHE III score 73.0 (59.0–87.0) 90.0 (75.0–105.0) ,.0001
Lowest WBC count (1000/mm
3) 12.1 (6.7–16.0) 11.6 (7.4–17.4) .61
Highest WBC count (1000/mm
3) 16.1 (11.0–20.8) 16.4 (11.3–24.3) .70
Lowest mean arterial pressure (mm Hg) 58.0 (54.0–63.0) 56.0 (51.0–60.0) .04
Need for vasopressor therapy 64 (60%) 47 (67%) .32
Serum BUN (mg/dL) 23.0 (14.0–37.0) 34.0 (20.0–50.0) .03
Serum creatinine (mg/dL) 1.2 (0.9–1.9) 1.5 (0.8–2.2) .59
24-hour urine output (cc) 1687.5 (1082–2560) 1214.0 (710–1940) .008
Serum total bilirubin (mg/dL) 0.7 (0.4–1.1) 0.90 (0.5–2.5) .01
Red blood cell units transfused 1.5 (0–3.0) 2 (0–4.0) .16
Platelet count 178.0 (116.0–263.0) 193.5 (80.0–267.0) .35
Tidal volume (cc per kg of ideal body weight) 9.1 (7.6–10.7) 8.0 (7.0–10.1) .07
Positive End-Expiratory Pressure (cm H2O) 10.0 (6.0–10.0) 8.0 (5.0–12.0) .43
Continuous variables are presented as median (interquartile range), categorical variables as number of patients in each category and (% of the total category).
doi:10.1371/journal.pone.0040515.t001
Troponin-T in Acute Respiratory Distress Syndrome
PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e40515previous echocardiograms; in the remainder it was unchanged
from prior studies, or no previous echocardiogram was available
for comparison.
Tables 5 and 6, respectively, show echocardiogram and
electrocardiogram characteristics for the study population, strat-
ified by presence or absence of elevated cTnT. Patients with cTnT
above the selected cut-point were significantly more likely to have
echocardiographic evidence of regional wall motion abnormalities.
Six out of the sixteen patients with echocardiographic wall motion
abnormalities had prior echocardiograms available for compari-
son. Only three patients had wall motion abnormalities that were
verifiably new compared to previous studies, and only two of these
three were in the group with elevated cTnT. Patient with elevated
cTnT had a higher median grade of tricuspid regurgitation (TR)
than did patients with lower cTnT (P =0.04). There were no
significant differences in ECG characteristics between the two
groups, although there was a borderline significant association
between presence of pathologic Q waves in patients with elevated
cTnT vs. patients with normal cTnT (26% vs. 7%, P=0.053).
However, pathological Q waves were only noted in a total of 9
patients in the cohort. There was no relationship between the
presence of ECG Q waves and echocardiographic regional wall
motion abnormalities (P=.60).
Given the increased proportion of echocardiograms obtained in
patients with septic shock or pneumonia, we sought to evaluate
whether these results were confounded by the presence or absence
of these diagnoses. We found no difference in the proportion of
regional wall motion abnormalities present between patients with
and without pneumonia (P=.23) or with and without septic shock
(P=.74). Likewise, we found no differences between median TR
grade between patients with and without pneumonia (P=.81) or
those with and without septic shock (P=.11).
Discussion
We have shown that cTnT levels are frequently elevated in
patients with ARDS, and that cTnT elevation is associated with
adverse outcomes, including death, organ failure, and need for
mechanical ventilation. The association of increasing cTnT level
with mortality from ARDS remains consistent after adjustment for
other factors involved in outcome and is robust through a variety
of statistical analyses. A multivariate model for mortality that
includes cTnT shows a statistically stronger association than for
the well-accepted APACHE III prognostic score. In addition, we
have shown that there were few significant differences in
electrocardiographic and echocardiographic parameters between
Figure 1. Relationship between cTnT log quartile and mortality, with superimposed trend line. (P value stated for Cochran-Armitage test
of trend).
doi:10.1371/journal.pone.0040515.g001
Table 2. Results of Cox proportional hazards model for
association of elevated cardiac troponin T level with 60-day
Mortality.
Variable Hazard Ratio 95% CI P
cTnT (per 1 ng/mL) 1.44 1.14–1.81 .002
Age (per year) 1.04 1.02–1.06 ,.0001
APACHE III (per point) 1.02 1.01–1.03 .007
Coronary artery disease 1.39 0.83–2.33 .20
Acute hepatic failure 4.25 1.31–13.75 .02
doi:10.1371/journal.pone.0040515.t002
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test).
doi:10.1371/journal.pone.0040515.g002
Figure 3. Daily MODS score by cTnT stratum. (Vertical bars indicate standard error of means, P value stated for repeated-measures ANOVA).
doi:10.1371/journal.pone.0040515.g003
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particular, it did not appear that patients with ARDS and elevated
cTnT are having missed classical (or ‘‘type 1’’) acute MIs or other
variants of the acute coronary syndrome.
There are multiple mechanisms whereby myocardial necrosis
may occur in ARDS patients. It is plausible that the pathogenesis
is akin to that of myocardial injury sustained by patients with
severe sepsis/septic shock [21]. However, these results show that
many ARDS patients had detectable cTnT levels even in the
absence of suspected infection. Moreover, plasma cTnT had
independent value in predicting mortality when compared with
the myriad clinical data represented by the APACHE III score.
This suggests that myocardial necrosis could be important in the
pathogenesis of ARDS beyond being a hallmark of systemic
disease such as septic shock. However, some of the molecular
mechanisms postulated to be involved in septic myocardial
dysfunction may also be in play in ARDS even in the absence of
infection or shock, including circulating proinflammatory media-
tors, nitric oxide activity, matrix metalloproteinase activation,
mitogen-activated protein kinase activity, and induction of cellular
apoptosis [21].
Table 3. Characteristics of patients who received echocardiogram or ECG testing.
Echo not done (n=96) Echo done (n=81) P
Age (years)* 61.0 (45.0–77.0) 65.0 (49.0–74.0) .74
APACHE III score 78.0 (65.0–97.0) 80.0 (70.0–96.0) .51
cTnT level (ng/mL) 0.03 (0–0.09) 0.02 (0–0.1) .90
Female gender 41 (44%) 36 (44%) .96
Caucasian race 86 (92%) 76 (94%) .73
Pneumonia 61 (66%) 68 (84%) .006
Septic shock 48 (52%) 55 (68%) .03
Sepsis (w/o shock) 32 (34%) 21 (26%) .23
Trauma 5 (5%) 2 (2%) .33
Aspiration 9 (10%) 6 (7%) .59
Multiple transfusions 10 (11%) 4 (5%) .16
Acute hepatic failure 4 (4%) 0 (0%) .06
Known coronary artery disease 23 (24%) 21 (26%) .82
Prior myocardial infarction 14 (15%) 12 (15%) .99
Prior coronary artery bypass grafting 3 (3%) 7 (9%) .12
Hyperlipidemia history 19 (20%) 14 (17%) .62
Hypertension history 39 (42%) 35 (43%) .82
Congestive heart failure 11 (12%) 7 (9%) .51
ECG not done (n=121) ECG done (n=56) P
Age (years)* 63.0 (45.0–74.0) 63.0 (47.0–77.0) .45
APACHE III score 80.0 (66.0–99.0) 76.0 (68.0–95.0) .48
cTnT level (ng/mL) 0.03 (0–0.08) 0.03 (0–0.12) .60
Female gender 57 (48%) 20 (36%) .15
Caucasian race 108 (91%) 54 (98%) .07
Pneumonia 91 (76%) 38 (69%) .30
Septic shock 65 (55%) 38 (69%) .07
Sepsis (w/o shock) 41 (34%) 12 (22%) .09
Trauma 4 (3%) 3 (5%) .51
Aspiration 11 (9%) 4 (7%) .67
Multiple transfusions 7 (6%) 7 (12%) .12
Acute hepatic failure 3 (3%) 1 (2%) .77
Known coronary artery disease 28 (24%) 16 (29%) .47
Prior myocardial infarction 17 (14%) 9 (16%) .76
Prior coronary artery bypass grafting 7 (6%) 3 (5%) .89
Hyperlipidemia history 22 (18%) 11 (20%) .86
Hypertension history 46 (39%) 28 (50%) .16
Congestive heart failure 12 (10%) 6 (11%) .90
Continuous variables are presented as median (interquartile range), categorical variables as number of patients in each category and (% of the total category).
doi:10.1371/journal.pone.0040515.t003
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limiting atherosclerotic lesions due to CHD may predispose
individuals to ischemic myocardial necrosis in the setting of
increasing myocardial oxygen demand and reduced coronary
blood flow due to critical illness (so-called type II MI). Supporting
this explanation are the findings of more regional wall motion
abnormalities and a trend toward more pathologic Q waves in the
group with elevated cTnT, which may indicate a greater
penetrance of CHD and flow-limiting coronary lesions in that
group. Contradicting this explanation, however, are data that
coronary blood flow is increased, not decreased, in patients with
septic shock, and that elevated troponin levels in a majority of
critically ill patients were not associated with flow-limiting
atherosclerotic coronary artery lesions in a prior study [22,23].
Furthermore, we did not observe significant differences between
patients with and without cTnT elevations with respect to any
ECG signs of active myocardial ischemia or acute coronary
syndromes. While patients with elevated cTnT were more likely to
have regional wall motion abnormalities on echocardiography,
which can be present in both active cardiac ischemia and in
patients with a history of myocardial infarction, this finding is not
specific to CHD and was seen in a minority of patients. It is
possible that patients with ARDS may be at risk of demand-related
myocardial ischemia independent of CHD. In this scenario,
cardiac biomarker elevation from such type II myocardial
infarctions may not be associated with classic electrocardiographic
signs of ischemia or specific findings on echocardiography. Further
research is needed in patients with ARDS to investigate both the
significance of regional wall motion abnormalities and the
possibility of demand-related myocardial ischemia in the setting
of biomarker evidence of myocardial necrosis.
Pulmonary vascular disease and associated right ventricular
strain are likely contributors to myocardial necrosis in ARDS. In
particular, pulmonary vascular disease is known to accompany
ARDS, and hemodynamic evidence of right ventricular strain has
been implicated in poorer prognosis [8,24]. Other reports have
shown that increased pulmonary dead space and radiologically-
determined pulmonary vascular obstruction are associated with
worse outcomes in ARDS [25,26]. Surprisingly, our data show
that patients with elevated cardiac biomarkers are no more likely
to show right ventricular hypokinesis, right ventricular dilation, or
elevated right ventricular systolic pressure on transthoracic
Table 4. Echocardiogram and electrocardiogram
characteristics of study population.
a
Echocardiographic characteristics (n=81)
Left ventricular ejection fraction (%) 57 (43–67)
Left atrial size (mm) 35 (30–40)
Left ventricular systolic size (mm) 32 (26–36)
Left ventricular diastolic size (mm) 44 (39–50)
Posterior wall thickness (mm) 10 (9–12)
Interventicular septal thickness (mm) 10 (8–12)
Left ventricular mass (grams)
b 145.4 (112.5–191.3)
Right ventricular systolic pressure (mm Hg) 44 (38–53)
Mitral regurgitation grade
c 1 (1–2)
Tricuspid regurgitation grade
c 2 (1–2.5)
Regional wall motion abnormalities 16 (20%)
Right ventricular dilation 19 (24%)
Right hypokinesis 18 (23%)
Electrocardiographic characteristics (n=56)
Ventricularly paced 4 (7.1%)
ECG with any sign of ischemia 23 (41%)
ST elevation 1 (1.8%)
ST depression 5 (8.9%)
T wave inversion 10 (18%)
T wave flattening 8 (14%)
Left bundle branch block 2 (3.6%)
aFor patients with a recorded echocardiogram or electrocardiogram within 48
hours of biomarker draw date. Continuous variables are presented as median
(interquartile range), categorical variables as number of patients and (% of
patients with available data).
bLV mass calculated using: Left ventricular mass (g)=0.8 61.04 6[(Left
ventricular end diastolic size + interventricular septal thickness + posterior wall
thickness)
3– left ventricular end diastolic size
3] +0.6.
cValvular regurgitation variables defined as follows: 0=none, 1=trace, 2=mild,
3=moderate, 4=severe.
doi:10.1371/journal.pone.0040515.t004
Table 5. Echocardiogram characteristics, by cardiac marker status (n=81).
a
Echocardiographic characteristics
Positive troponin
(TnT $0.03)
Negative troponin
(TnT ,0.03) P**
Left ventricular ejection fraction (%) 57.5 (40–71) 56 (48–67) 0.87
Left atrial size (mm) 35.0 (31.5–40.5) 34.5 (29.0–39.0) 0.87
Left ventricular mass (grams)
b 147.8 (113.6–186.6) 142.9 (100.6–205.5) 0.89
Right ventricular systolic pressure 44.5 (38–58) 42 (39–51) 0.55
Mitral regurgitation grade
c 1 (1–2) 1 (0–2) 0.24
Tricuspid regurgitation grade
c 2 (1.75–2.75) 2 (1–2) 0.04
Regional wall motion abnormalities 13 (37%) 3 (7%) 0.001
Right ventricular dilation 9 (25%) 10 (23%) 0.86
Right ventricular hypokinesis 9 (26%) 9 (21%) 0.62
aFor patients with a recorded echocardiogram within 48 hours of biomarker draw date. Continuous variables are presented as median (interquartile range), categorical
variables as number of patients and (% of patients with available data).
bFor continuous variables, value represents P value for rank sum test for difference in distributions, for categorical variables, value represents P value for Chi2 statistic.
cValvular regurgitation variables defined as follows: 0=none, 1=trace, 2=mild, 3=moderate, 4=severe.
doi:10.1371/journal.pone.0040515.t005
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The validity of our data is supported by our finding that between
22 and 33% of patients had evidence of right ventricular dilation
or hypokinesis, which is very similar to previously reported rates of
echocardiographically demonstrated acute cor pulmonale in
patients with ARDS [27]. There are other potential explanations
for the lack of correlation between cTnT and RV dysfunction.
First, pulmonary vascular disease in ARDS may be predominantly
microvascular and relatively sub-acute in onset, and thus obtaining
an echocardiogram within 48 hours of ARDS onset may be too
early for echocardiographic signs of right ventricular strain to
manifest differently in patients with and without biomarker
evidence of myocardial necrosis. Secondly, right ventricular strain
occurring in patients with ARDS may not be effectively captured
by a echocardiographic assessments of right ventricular hypoki-
nesis or systolic function, even if a substantial degree of strain is
present. Previous reports have shown that compared to magnetic
resonance imaging, echocardiographic reliability for accurately
identifying moderately to severely diminished right ventricular
function was slight to fair, with poor inter-rater agreement [28].
There are abundant data that echocardiographically obtained
pulmonary artery and right ventricular systolic pressures are
inaccurate, and do not correlate well with measurements made
during gold standard right heart catheterization, even in patients
with known pulmonary hypertension [29–31]. Conversely, echo-
cardiographic determination of the presence and severity of
tricuspid regurgitation is highly accurate, and correlates well with
assessments made by right ventriculography [32,33]. In our study
participants, there was a significantly greater median grade
tricuspid regurgitation in patients with elevated cTnT than
inpatients with negative biomarkers. Given the high reliability of
echocardiographic determinations of triscuspid regurgitation, this
may represent a meaningful difference in right sided heart function
between the two groups that is not evident from other
echocardiographic measurements. Previous reports have demon-
strated that tricuspid regurgitation is a common finding in the
critical care setting in conditions known to be characterized by
right ventricular strain, such as acute pulmonary embolism [34]. A
final explanation for the discrepancy between cTnT and
echocardiographic evidence of RV dysfunction is that right
ventricular strain with myocardial necrosis my be common in
patients with ARDS, and may be independent of disease severity
as marked by elevated cTnT.
The strengths of this study include its prospective nature and
well-characterized population. Use of NAECC criteria to define
ARDS limits misclassification bias related to the lack of a
diagnostic gold-standard. We dealt with bias inherent to the prior
study by including only cTnT assays in our study and blinding
investigators to the clinical status of patients. This is a potential
reason that we did not find evidence of the previously suggested
effect modification by age or severity of illness. In the prior study,
the decision to test for biomarkers of myocardial necrosis was
made by unblinded clinicians; patients who had blood tested for
biomarker levels were significantly more likely to be older and to
have higher severity of illness scores than those who were not
tested. In addition, the analysis of available echocardiographic and
ECG data for a portion of study patients allowed us to evaluate for
the presence of preexisting or concomitant CHD and ACS, which
may obviously influence biomarker levels in this clinical setting.
Historically, much attention has been paid to using physiologic
measurements to assess for severity of illness in ARDS. However,
such measurements may be cumbersome to perform, require
extensive training, or pose substantial risks to patients. Recent
research has focused on the definition of molecular phenotypes
using biomarker analysis. This has included attempts to detect or
quantify various aspects of ARDS pathophysiology, including
systemic inflammation, alveolar-capillary leak, and altered coag-
ulation [35–38]. Thus far these efforts have ranged from highly
targeted approaches that study either single or small groups of
biomarkers, to more expansive and ambitious efforts that attempt
to analyze the entire proteome of such patients [39]. Our
approach shows that biomarkers of myocardial necrosis such as
cTnT may comprise an important part of attempts to further
define the molecular phenotype of ARDS.
We acknowledge the presence of several limitations of our study.
As a general limitation, the design of this study makes it difficult to
generalize the results to other populations of patients, including
the immunocompromised or patients with risk factors for ARDS
other than those studied. In terms of the data available,
echocardiographic and ECG results were only available for a
portion of the study patients, as the decision to obtain these studies
was made by treating physicians in the process of routine clinical
care. Therefore these data are limited by absence of data for all
study patients, thus introducing potential selection bias. To
address this issue, we compared characteristics of patients who
received echocardiogram/ECG and those who did not, and found
few differences between these groups. We did find that pneumonia
or septic shock were more frequently present in patients who had
echocardiograms, but there was no evidence of confounding
between these initial diagnoses and the presence of the reported
echocardiographic abnormalities. In addition, because of the small
numbers of echocardiograms and electrocardiograms available for
analysis, the power of these analyses to detect small differences is
limited. A further limitation was our inability to capture serial
Table 6. Electrocardiogram characteristics, by cardiac marker status (n=56).
a
Electrocardiographic characteristics
Positive troponin
(TnT $0.03)
Negative troponin
(TnT ,0.03) P
ECG with any sign of ischemia 13 (48%) 10 (35%) 0.30
ST elevation 0 (0%) 1 (4%) 0.49
ST depression 4 (15%) 1 (4%) 0.14
Pathologic Q waves 7 (26%) 2 (7%) 0.05
T wave inversion 5 (19%) 5 (17%) 0.87
T wave flattening 6 (22%) 2 (7%) 0.10
Left bundle branch block 1 (4%) 1 (4%) 0.96
aVariables are presented as number of patients and (% of patients with available data).
doi:10.1371/journal.pone.0040515.t006
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demonstrated that in patients with severe acute respiratory failure,
initial levels of pulmonary artery pressure or pulmonary vascular
resistance were not prognostic [8]. However, the failure of
pulmonary artery pressure and pulmonary vascular resistance to
fall over time was associated with decreased survival. It is therefore
possible that had we obtained serial echocardiograms for our study
participants, we may have found a correlation between biomarker
evidence of myocardial necrosis and echocardiographic measures
of right ventricular or pulmonary artery hemodynamics. For
similar reasons, it would have been ideal to capture serial
measurements of cTnT to determine whether the relationship
between biomarker level, cardiac function, and prognosis vary
with serial measurement. Future studies should continue to further
explore troponin elevation with regard to cardiac function in
hopes of clarifying their relationship, and we hope this study
stimulates interest in such research. In particular, new-generation
high-sensitivity troponin assays have recently become available
[40]. These assays can detect troponin in the blood at levels
considerably lower than can be measured by conventional assays.
Since troponin levels in this population tended to be in the lower
ranges of the assay, high-sensitivity assays might improve
predictive ability and should be examined in future studies.
Conclusions
We have shown that biomarker evidence of myocardial injury is
associated with worsened outcomes in patients with ARDS, and
that this appears to be independent of other systemic factors such
as severity of illness or the presence of infection. In addition,
elevated cardiac-specific biomarkers in this population are
associated with regional wall motion abnormalities and with
triscuspid valve dysfunction by echocardiography, but are not
associated with ECG evidence of acute coronary syndrome. This
research raises the potential importance of cardiac function in
ARDS and contributes to efforts to establish define molecular
phenotypes in this syndrome. Further investigation is warranted to
define these relationships and apply the information garnered to
the tasks of diagnosis, management, and prognostication.
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